Five form 5 filed with SEC of insiders buying.
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum -- Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease - Estimated primary completion date October 2015. Estimated Study completion date December 2015